NASDAQ:SYBX

Synlogic Competitors

$3.33
-0.01 (-0.30 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.27
Now: $3.33
$3.47
50-Day Range
$3.09
MA: $3.84
$4.90
52-Week Range
$1.74
Now: $3.33
$5.11
Volume192,351 shs
Average Volume1.07 million shs
Market Capitalization$132.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2

Competitors

Synlogic (NASDAQ:SYBX) Vs. ETNB, RAPT, FBIO, AVDL, PRVB, and NLTX

Should you be buying SYBX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Synlogic, including 89bio (ETNB), RAPT Therapeutics (RAPT), Fortress Biotech (FBIO), Avadel Pharmaceuticals (AVDL), Provention Bio (PRVB), and Neoleukin Therapeutics (NLTX).

89bio (NASDAQ:ETNB) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of recent ratings for 89bio and Synlogic, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
89bio00613.14
Synlogic01402.80

89bio currently has a consensus target price of $62.4286, indicating a potential upside of 137.55%. Synlogic has a consensus target price of $13.25, indicating a potential upside of 297.90%. Given Synlogic's higher possible upside, analysts clearly believe Synlogic is more favorable than 89bio.

Profitability

This table compares 89bio and Synlogic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
89bioN/A-49.56%-46.52%
Synlogic-2,761.83%-41.64%-34.39%

Valuation and Earnings

This table compares 89bio and Synlogic's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
89bioN/AN/A$-57,420,000.00($24.49)-1.07
Synlogic$2.22 million59.49$-51,370,000.00($1.70)-1.96

Synlogic has higher revenue and earnings than 89bio. Synlogic is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 39.5% of Synlogic shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 18.0% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Synlogic beats 89bio on 7 of the 13 factors compared between the two stocks.

Synlogic (NASDAQ:SYBX) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Synlogic and RAPT Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$2.22 million59.49$-51,370,000.00($1.70)-1.96
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-2.13

RAPT Therapeutics has lower revenue, but higher earnings than Synlogic. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and RAPT Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synlogic-2,761.83%-41.64%-34.39%
RAPT TherapeuticsN/A-48.78%-42.35%

Analyst Ratings

This is a breakdown of recent ratings for Synlogic and RAPT Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synlogic01402.80
RAPT Therapeutics00503.00

Synlogic currently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. RAPT Therapeutics has a consensus price target of $41.20, suggesting a potential upside of 95.82%. Given Synlogic's higher possible upside, analysts plainly believe Synlogic is more favorable than RAPT Therapeutics.

Institutional & Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 65.0% of RAPT Therapeutics shares are held by institutional investors. 18.0% of Synlogic shares are held by insiders. Comparatively, 31.0% of RAPT Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500.

Summary

Synlogic beats RAPT Therapeutics on 7 of the 13 factors compared between the two stocks.

Synlogic (NASDAQ:SYBX) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Synlogic and Fortress Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$2.22 million59.49$-51,370,000.00($1.70)-1.96
Fortress Biotech$36.63 million14.09$-39,960,000.00($0.73)-7.45

Fortress Biotech has higher revenue and earnings than Synlogic. Fortress Biotech is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Fortress Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synlogic-2,761.83%-41.64%-34.39%
Fortress Biotech-131.98%-44.08%-19.06%

Analyst Ratings

This is a breakdown of recent ratings for Synlogic and Fortress Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synlogic01402.80
Fortress Biotech00603.00

Synlogic currently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Fortress Biotech has a consensus price target of $10.75, suggesting a potential upside of 97.61%. Given Synlogic's higher possible upside, analysts plainly believe Synlogic is more favorable than Fortress Biotech.

Institutional & Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 32.1% of Fortress Biotech shares are held by institutional investors. 18.0% of Synlogic shares are held by insiders. Comparatively, 29.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Summary

Fortress Biotech beats Synlogic on 9 of the 14 factors compared between the two stocks.

Synlogic (NASDAQ:SYBX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Valuation and Earnings

This table compares Synlogic and Avadel Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$2.22 million59.49$-51,370,000.00($1.70)-1.96
Avadel Pharmaceuticals$59.22 million8.67$-33,230,000.00($0.89)-9.87

Avadel Pharmaceuticals has higher revenue and earnings than Synlogic. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Avadel Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synlogic-2,761.83%-41.64%-34.39%
Avadel Pharmaceuticals38.70%-33.91%-11.75%

Analyst Ratings

This is a breakdown of recent ratings for Synlogic and Avadel Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synlogic01402.80
Avadel Pharmaceuticals00603.00

Synlogic currently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Avadel Pharmaceuticals has a consensus price target of $18.60, suggesting a potential upside of 111.85%. Given Synlogic's higher possible upside, analysts plainly believe Synlogic is more favorable than Avadel Pharmaceuticals.

Institutional & Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 53.8% of Avadel Pharmaceuticals shares are held by institutional investors. 18.0% of Synlogic shares are held by insiders. Comparatively, 1.4% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Summary

Avadel Pharmaceuticals beats Synlogic on 10 of the 14 factors compared between the two stocks.

Synlogic (NASDAQ:SYBX) and Provention Bio (NASDAQ:PRVB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Institutional and Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 39.4% of Provention Bio shares are held by institutional investors. 18.0% of Synlogic shares are held by company insiders. Comparatively, 14.4% of Provention Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Synlogic and Provention Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$2.22 million59.49$-51,370,000.00($1.70)-1.96
Provention BioN/AN/A$-43,280,000.00($1.06)-7.55

Provention Bio has lower revenue, but higher earnings than Synlogic. Provention Bio is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Provention Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synlogic-2,761.83%-41.64%-34.39%
Provention BioN/A-67.66%-62.27%

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Provention Bio has a beta of 3.34, suggesting that its stock price is 234% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Synlogic and Provention Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synlogic01402.80
Provention Bio01502.83

Synlogic presently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Provention Bio has a consensus price target of $25.50, suggesting a potential upside of 218.75%. Given Synlogic's higher possible upside, equities research analysts clearly believe Synlogic is more favorable than Provention Bio.

Summary

Synlogic beats Provention Bio on 7 of the 13 factors compared between the two stocks.

Synlogic (NASDAQ:SYBX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings.

Institutional and Insider Ownership

39.5% of Synlogic shares are held by institutional investors. Comparatively, 65.7% of Neoleukin Therapeutics shares are held by institutional investors. 18.0% of Synlogic shares are held by company insiders. Comparatively, 7.1% of Neoleukin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Synlogic and Neoleukin Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$2.22 million59.49$-51,370,000.00($1.70)-1.96
Neoleukin Therapeutics$25 million20.27$-69,440,000.00($0.75)-15.96

Synlogic has higher earnings, but lower revenue than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Neoleukin Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synlogic-2,761.83%-41.64%-34.39%
Neoleukin TherapeuticsN/A-24.06%-21.92%

Risk and Volatility

Synlogic has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500. Comparatively, Neoleukin Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Synlogic and Neoleukin Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synlogic01402.80
Neoleukin Therapeutics00603.00

Synlogic presently has a consensus price target of $13.25, suggesting a potential upside of 297.90%. Neoleukin Therapeutics has a consensus price target of $22.6667, suggesting a potential upside of 89.36%. Given Synlogic's higher possible upside, equities research analysts clearly believe Synlogic is more favorable than Neoleukin Therapeutics.

Summary

Neoleukin Therapeutics beats Synlogic on 8 of the 14 factors compared between the two stocks.


Synlogic Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
89bio logo
ETNB
89bio
1.6$26.28-0.2%$524.18 millionN/A-5.20
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$21.04-5.1%$523.18 millionN/A-8.28News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44-10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.78-0.0%$513.32 million$59.22 million43.90News Coverage
Provention Bio logo
PRVB
Provention Bio
1.6$8.00-21.6%$507 millionN/A-5.37Analyst Report
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.97-0.9%$506.64 million$25 million-18.42
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.00-0.3%$502.28 million$58.12 million-16.28
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.72-1.2%$500.13 million$57.49 million-6.49
XBiotech logo
XBIT
XBiotech
1.0$16.95-0.4%$499.33 millionN/A1.17
AC Immune logo
ACIU
AC Immune
1.3$6.87-0.6%$494.21 million$111.75 million-7.63
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.53-6.6%$494.19 millionN/A-2.59Gap Down
Altimmune logo
ALT
Altimmune
1.9$12.90-1.7%$479.24 million$5.80 million-6.48
Akouos logo
AKUS
Akouos
1.6$13.87-1.4%$477.16 millionN/A0.00News Coverage
Verastem logo
VSTM
Verastem
1.1$2.76-1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07-3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48-2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$4.18-2.4%$469.72 million$6.68 million-5.04
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.06-3.3%$469.72 million$335 million-1.03Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.63-3.4%$466.82 million$56.50 million0.00Analyst Upgrade
Gap Up
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.57-4.1%$465.95 million$6.07 million-3.62Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23-0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
BCEL
Atreca
1.7$12.29-3.4%$452.65 millionN/A-4.36Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$12.29-3.1%$452.48 millionN/A0.00Gap Up
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.33-2.3%$449.56 million$102.31 million6.46
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$19.02-1.4%$446.29 millionN/A0.00News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8N/AN/A$439.81 millionN/A-3.55
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.92-3.9%$438.87 millionN/A-12.08News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.3$38.99-0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
Sesen Bio logo
SESN
Sesen Bio
1.2$2.52-3.2%$426.85 millionN/A-5.73Gap Down
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.45-0.4%$426.64 million$380,000.000.00Analyst Upgrade
DURECT logo
DRRX
DURECT
1.4$1.85-1.6%$420.32 million$29.56 million-36.99
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.66-0.6%$415.41 million$9.48 million-0.28
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$8.26-13.1%$407.75 million$2.42 million-7.25Analyst Report
Unusual Options Activity
Analyst Revision
Gap Up
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$8.12-2.2%$405.38 million$72.96 million-2.63Gap Down
BeyondSpring logo
BYSI
BeyondSpring
1.2$10.29-3.2%$402.77 millionN/A-5.04Gap Down
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.53-4.9%$402.50 million$1.98 million-3.93Gap Down
UroGen Pharma logo
URGN
UroGen Pharma
1.8$19.20-1.1%$401.22 million$20,000.00-3.00
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$31.86-0.3%$393.95 million$206.55 million-16.01
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.5$11.87-0.4%$387.82 millionN/A-4.12News Coverage
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.44-3.5%$387.10 million$28.91 million-5.73Analyst Downgrade
News Coverage
Gap Up
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$19.55-2.3%$387.01 million$362.21 million23.55Gap Down
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$13.08-2.4%$385.91 million$18.15 million-3.08
Athenex logo
ATNX
Athenex
1.6$4.10-4.6%$383.17 million$101.23 million-2.81Gap Down
Athersys logo
ATHX
Athersys
1.3$1.78-7.3%$383.14 million$5.63 million-4.81Gap Down
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.7$1.18-1.7%$382.22 millionN/A-0.33Analyst Revision
News Coverage
Gap Up
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.6$9.33-1.1%$375.61 million$272.30 million-6.52
Cue Biopharma logo
CUE
Cue Biopharma
1.3$12.28-1.0%$374.01 million$3.46 million-7.82
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.96-12.7%$373.27 million$16.54 million-3.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$10.84-0.9%$370.49 million$28.95 million-15.49Unusual Options Activity
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.71-0.4%$370.20 million$3.89 million-4.04
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.